Product information and disease descriptionPlace of product in therapyApproaches to treatment
Ongoing post-approval monitoring
1 evidence topic · 1 source
United Kingdom 1.5 mg tablets: suspected adverse-reaction reporting
| Reporting route | Quoted scheme |
|---|---|
| National adverse-reaction reporting system | “Yellow Card Scheme” |
U.S. post-approval monitoring
Not applicable.